Dexchlorpheniramine, dextromethorphan, and pseudoephedrine and Dextromethorphan Hydrobromide and Quinidine Sulfate

• Generic Name: dexchlorpheniramine / dextromethorphan / pseudoephedrine
• Dosage Forms: n.a.
• Other Brand Names: Abatuss DMX, Bromatan Plus, SuTan-DM, Tanafed DMX, Tannate DMP-DEX, C-Phed DPD Tann, Tanafed-DMX, DuraTan Forte, Dur-Tann Forte, TanDur DM, Tannate PD-DM, Deltuss DMX

Dexchlorpheniramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Dexchlorpheniramine, dextromethorphan, and pseudoephedrine is a combination medicine used to treat runny or stuffy nose, sneezing, itching, watery eyes, cough, and sinus congestion caused by allergies, the common cold, or the flu.

dexchlorpheniramine, dextromethorphan, and pseudoephedrine will not treat a cough that is caused by smoking, asthma, or emphysema.

Dexchlorpheniramine, dextromethorphan, and pseudoephedrine may also be used for purposes not listed in this medication guide.

• Generic Name: dextromethorphan / quinidine
• Dosage Forms: n.a.
• Other Brand Names: Nuedexta

The fixed combination of dextromethorphan hydrobromide and quinidine sulfate (dextromethorphan/quinidine; Nuedexta) is used in the treatment of PBA.

PBA occurs secondary to various otherwise unrelated neurologic conditions (e.g., amyotrophic lateral sclerosis [ALS], multiple sclerosis [MS], dementia of the Alzheimer's type [Alzheimer's disease] or other dementia, parkinsonian syndrome, stroke, traumatic brain injury) and is characterized by involuntary, sudden, uncontrollable, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

Studies supporting efficacy in PBA were conducted in patients with underlying ALS or MS.

Safety and efficacy in the treatment of other common types of emotional lability (e.g., those occurring in patients with Alzheimer's disease and other dementias) not established.